Aerovate Therapeutics, Inc.

NasdaqGM:AVTE Rapporto sulle azioni

Cap. di mercato: US$55.7m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Aerovate Therapeutics Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Tim Noyes

Amministratore delegato

US$3.1m

Compenso totale

Percentuale dello stipendio del CEO19.1%
Mandato del CEO3.3yrs
Proprietà del CEOn/a
Durata media del management2.8yrs
Durata media del Consiglio di amministrazione3.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market

Jun 11

Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

May 24
Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Feb 09
Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate

Oct 17
We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Jul 04
Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Feb 28
Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Jan 06
A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Oct 14
Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

Jul 01
Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth

Jan 22
We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Sep 30
Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Tim Noyes rispetto agli utili di Aerovate Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$88m

Mar 31 2024n/an/a

-US$82m

Dec 31 2023US$3mUS$586k

-US$76m

Sep 30 2023n/an/a

-US$70m

Jun 30 2023n/an/a

-US$64m

Mar 31 2023n/an/a

-US$57m

Dec 31 2022US$704kUS$563k

-US$52m

Sep 30 2022n/an/a

-US$45m

Jun 30 2022n/an/a

-US$37m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$5mUS$437k

-US$23m

Compensazione vs Mercato: La retribuzione totale di Tim ($USD 3.07M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).

Compensazione vs guadagni: La retribuzione di Tim è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Tim Noyes (62 yo)

3.3yrs

Mandato

US$3,070,657

Compensazione

Mr. Timothy P. Noyes, MBA, also known as Tim, has been the Chief Executive Officer of Aerovate Therapeutics, Inc. since May 2021 and has been its Director since April 2021. Mr. Noyes serves as Venture Part...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Timothy Noyes
CEO & Director3.3yrsUS$3.07mNessun dato
George Eldridge
CFO & Treasurer3.5yrsUS$2.13m0.017%
$ 9.7k
Timothy Pigot
Chief Commercial Officer3.3yrsUS$2.45m0.011%
$ 6.3k
Benjamin Dake
Founder6.2yrsUS$2.88m0.049%
$ 27.5k
Marinus Verwijs
Chief Technical Officer1.3yrsUS$1.32mNessun dato
Ralph Niven
Chief Scientific Officer2.1yrsUS$433.20k0.0056%
$ 3.1k
Hunter Gillies
Chief Medical Officer4.3yrsUS$1.63m0.019%
$ 10.8k
Donna Dea
Head of Regulatory Affairs4yrsNessun datoNessun dato
Susan Fischer
Executive Vice President of Development Operations2.4yrsNessun datoNessun dato
Stephen Yu
Senior Vice President of Quality2.1yrsNessun datoNessun dato
Sanjeev Khindri
Executive Vice President of Clinical Development1.7yrsNessun datoNessun dato
Cheryl Lassen
Senior Vice President of Clinical Development1.7yrsNessun datoNessun dato

2.8yrs

Durata media

58yo

Età media

Gestione esperta: Il team dirigenziale di AVTE è considerato esperto (durata media dell'incarico 2.8 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Timothy Noyes
CEO & Director3.4yrsUS$3.07mNessun dato
Maha Katabi
Independent Director4.1yrsUS$230.01k0%
$ 0
Christian Schade
Independent Director1.2yrsNessun datoNessun dato
Donald Santel
Independent Director1.7yrsUS$568.54k0%
$ 0
David Grayzel
Independent Director4.1yrsUS$225.99k0%
$ 0
Joshua Resnick
Independent Director4.1yrsUS$174.80k0%
$ 0
Mark Iwicki
Independent Director3.6yrsUS$218.30k0%
$ 0
Allison Dorval
Independent Director3.2yrsUS$185.80k0%
$ 0
Habib Dable
Independent Chairman of the Board1.2yrsUS$363.25k0%
$ 0

3.4yrs

Durata media

56yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AVTE sono considerati esperti (durata media dell'incarico 3.3 anni).